Poor prognostic factors (PPFs) are used in practice to predict disease course; however, there are questions regarding the utility of PPFs to predict outcomes, including radiographic progression.

In the post hoc analyses reviewed in this paper, regardless of baseline predictors of prognosis, filgotinib groups showed additional treatment benefit compared to monotherapy with methotrexate (MTX).

PPFs were generally associated with greater changes in modified total Sharp scores, with trends toward greatest change in patients with more PPFs across treatment groups.

Benefits of filgotinib were observed in high-risk subgroups both in MTX-naïve patients and those with inadequate response to MTX.